This grant allows us to continue to participate in the activities and study protocols of the Southwest Oncology Group, which involves development and testing of investigational therapies in patients with solid tumor or hematologic malignancies that have less than 100% cure rates with standard therapies. We believe that the pooling of patient data from multiple institutions is a scientifically valid and efficient method for quickly evaluating new therapeutic strategies. We participate in three specific areas of this cooperative group process: (a) moderate but high quality patient accrual onto group studies, (b) scientific and administrative contributions to development and coordination of group studies, and (c) act as the administrative, scientific and quality control link between several community oncologist (Cancer Control Affiliates) and the Southwest Oncology Group. Over the past 4 years we have maintained patient accrual at 91- 125 patients per year with excellent quality of data with respect to patient evaluatibility and protocol compliance (1983 = 125 patients; 1984 = 91 patients; 1985 = 104 patients, 1986 = 111 patients). We expect to increase patient accrual to approximately 150 per year as group wide protocols in non-small cell and extensive small cell lung cancers, head and neck cancer and acute leukemia become available. The faculty at our institution are particularly strong in the areas of investigational new agents, biological response modifers, pharmacology, the development of new drug delivery systems and radiation. Expertise in these areas has allowed us to make major scientific contributions to SWOG in the development of new therapeutic strategies in several tumor types. We propose to continue and to increase our activity in this area. Several community oncologists in southeastern Michigan and northern Ohio who trained in our fellowship program and therefore had considerable experience with SWOG studies have recently become affiliates via the cooperative Group Outreach Program (CGOP). We hope to increase activity in this area. In turn, we anticipate that clinical research, patient care and training programs in oncology will be enhanced at our institution by our continued participation in the Southwest Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA027057-09
Application #
3556850
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1980-01-01
Project End
1992-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
9
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Prebet, Thomas; Sun, Zhuoxin; Ketterling, Rhett P et al. (2016) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol 172:384-91
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Whelan, Timothy J; Olivotto, Ivo A; Parulekar, Wendy R et al. (2015) Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 373:307-16
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64

Showing the most recent 10 out of 194 publications